Comment on ‘Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures’
Open Access
- 6 April 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 43 (5), 503-505
- https://doi.org/10.1007/s40264-020-00929-0
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adultsVox Sanguinis, 2019
- Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017Drug Safety, 2018
- A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemiaAmerican Journal of Hematology, 2017
- Safety of intravenous iron use in chronic kidney diseaseCurrent Opinion in Nephrology and Hypertension, 2016
- Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies ConferenceKidney International, 2016
- A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patientsNephrology Dialysis Transplantation, 2015
- The Safety of Intravenous Iron PreparationsMayo Clinic Proceedings, 2015
- Hypersensitivity reactions to intravenous iron: guidance for risk minimization and managementHaematologica, 2014
- Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trialNephrology Dialysis Transplantation, 2013
- A multicenter, randomized, active‐controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemiaTransfusion, 2013